NCT06786598 is a NA clinical trial of Cholesterol in Breast Cancer, sponsored by Tishreen University.

Who is sponsoring NCT06786598?

NCT06786598 is sponsored by Tishreen University.

What drugs are being tested in NCT06786598?

Interventions in NCT06786598: Cholesterol.

What condition does NCT06786598 study?

NCT06786598 studies Breast Cancer.

Is NCT06786598 still recruiting?

NCT06786598 is currently completed. Last updated 28 January 2025.

Last reviewed 2025-01-28 · How we verify

NCT06786598

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Body Mass Index and Total Cholesterol Levels on Histopathological Grading in Breast Cancer Patients

Completed NA Last updated 28 January 2025

What this trial tests

NA trial testing Cholesterol in Breast Cancer in 85 participants. Completed in 1 October 2023.

Timeline

1 January 2023

Primary endpoint
1 September 2023

1 October 2023

Quick facts

Lead sponsor	Tishreen University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	85
Start date	1 January 2023
Primary completion	1 September 2023
Estimated completion	1 October 2023
Sites	1 location across Syria

Drugs / interventions tested

Cholesterol (CHOLESTEROL) — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Tishreen University

Who can join

Eligibility, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Breast cancer is a widespread cancer that affects high percentiles of women worldwide.The development and aggressiveness of breast cancer cells can be evaluated depending on the histopathological grading which reflects the degree of differentiation. Several factors related to lifestyle can impact the development of breast cancer. Obesity is an important factor that received the attention in recent years. The using of body mass index(BMI) is still the common method for identifying obesity which is defined when having 30kg/m² or more. Previous epidemiological and clinical studies found that obesity was correlated with advanced breast cancer especially in postmenopausal patients . Also, the changes in cholesterol levels can influence breast cancer risk in the context of obesity. The findings of other studies is still controversial; many studies revealed that elevated total cholesterol levels could increase breast cancer risk while others found to have no effect. Due to the possibility of previous factors' effect on breast cancer progression, we purposed in this study to assess the association of BMI and total cholesterol with histopathological grading according to menopausal status among a group of breast cancer patients in Syria

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The effect of body mass index and total cholesterol levels on histopathological grading in breast cancer patients.
Hasan R, Abdalla N, Bilal M. · · 2025 · PMID 40852010 · DOI 10.1097/ms9.0000000000003371

Verify or expand the search:

Other trials of Cholesterol

Trials testing the same drug.

NCT00965068 — Cholesterol in ASD: Characterization and Treatment · Phase 1, PHASE2 · completed
NCT00001721 — Study of Smith-Lemli-Opitz Syndrome · completed

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Tishreen University trials

Trials by the same sponsor.

NCT07350421 — The Effectiveness of Inhaled Salbutamol in the Management of Transient Tachypnea of the Newborn(TTN) · NA · not yet recruiting
NCT07270042 — Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection · NA · not yet recruiting
NCT07099261 — A Comparative Clinical Study to Evaluate Crowns Designed by Artificial Intelligence Versus Crowns Designed Traditional D · NA · not yet recruiting
NCT07467759 — Benzydamine for Radiation-Induced Oral Mucositis in Patients Receiving High-Dose Radiotherapy · Phase 4 · completed
NCT07095946 — Effectiveness of Intraligament vs IANB Anesthesia in Children Using Electronic Syringe · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06786598 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tishreen University
Last refreshed: 28 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06786598.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing